



ADAllen Pharma
COMPARATOR DRUGS SPECIALIST



CARBON FOOTPRINT **ADALLEN PHARMA LTD** 2023

adallenpharma.com

Prepared by :



Eco Sourcing Hub
REDUCE COSTS, EMISSIONS & RISKS

GENERAL INFORMATION



This report presents the carbon footprint analysis for ADAllen Pharma Ltd.

Founded by CEO David Allen in 2001, ADAllen Pharma Ltd is a private company specialising in sourcing licensed comparator drugs, including biosimilars for clinical trials. The company has since expanded to include a range of services such as expert project management and specialist cold chain storage.

David Allen with over 30 years of experience in the pharmaceutical industry, began his career as a qualified pharmacist before establishing the clinical trial sourcing operations in the mid-90s. The company invests in ISO 9001:2015 BSI Accreditation to enhance processes and actively seeks customer feedback to ensure exceptional service.

ADAllen Pharma Ltd is committed to maintaining customer confidentiality and proactive sourcing while fostering strong supplier relationships to safeguard the UK pharmaceutical supply chain, prevent product shortages, and combat counterfeit medicine by sourcing directly from manufacturers.

The objective of this report is to communicate the inventory of greenhouse gas emissions with a focus on consistency, comparability, and completeness. It is designed for stakeholders interested in the greenhouse gas emissions inventory and associated reporting structure.

This report adheres to the Greenhouse Gas Protocol reporting standards, specifically the Corporate Accounting and Reporting Standard (2004) and the Corporate Value Chain Accounting and Reporting Standard (2011). We've maintained credibility through adherence to Accounting Principles such as Relevance, Completeness, Consistency, Transparency, and Accuracy, using primary data wherever possible and a cautious approach when primary data was unavailable.

This report covers the period from 1 January 2023 to 31 December 2023. The next iteration is expected to follow the same duration, with any deviations communicated upon publication.



ORGANISATIONAL BOUNDARIES

The organisational boundaries for this report were determined using the consolidation based on the **operational control** approach, encompassing all emissions over which ADAllen Pharma Ltd has operational control, regardless of financial control.

The company operates as a single entity with one shared headquarters, providing a comprehensive view of the overall environmental impact.



REPORTING BOUNDARIES

In this report 9 different sources of carbon emissions are considered, grouped in 4 blocks:



A. Direct - Direct emissions from operations that are owned or controlled by the reporting company.

1. Mobile Combustion - Emissions resulting from the combustion of fuels in company owned/controlled mobile combustion sources, however it is 0 as all the company's own vehicles are Electric.



B. Indirect

2. Electricity - Emissions resulting from the generation of electricity, purchased by the company.



C. Upstream - Indirect emissions that occur in the value chain related to purchased goods & services.

3. Goods & Services - Embedded emissions in purchased goods and services.



4. Energy Supply - Embedded emissions in the purchase of fuels and energy in other activity categories.



5. Transport Upstream - Emissions related to the transport of goods upstream of the production process or any transport purchased by the company.



REPORTING BOUNDARIES



6.Waste - Emissions related to the disposal and processing of waste generated in operations



7.Business Travel - Emissions related to transportation of employees for business-related activities.



8.Commuting - Emissions related to commutes of employees in vehicles not under control of the company.



D. Downstream - Indirect emissions that occur in the value chain related to sold goods & services.



9.Transport Downstream - Emissions related to the transport of goods downstream of the production process not paid for by the company.

This includes all relevant sources of greenhouse gas emissions. These were selected based on their relevance to the organisation's operations and/or their relative size in the total footprint.

R B



THE EXCLUDED EMISSION

The excluded emission categories are listed below. All these sources are identified as not applicable or not significant for the current reporting objectives.

- Stationary Combustion: Estimated size of the emissions is too small. ADAllen uses an electric boiler for heating.

- Fugitive Emissions Estimated size of the emissions is too small.

- Capital Goods: All purchased goods covered under Purchased goods and services.

- Upstream and Downstream Leased Assets: ADAllen doesn't lease or lease out assets.

- Processing Of Sold Products: ADAllen has no source of emission.

- Franchises ADAllen has no source of emission.


- Investments ADAllen has no source of emission.



QUANTIFIED GHG INVENTORY

In the reporting period Y-2023 the total emissions for the reporting organisation add up to **46 tCO₂e**.

The greenhouse gas emissions are expressed as tonnes of CO₂-equivalent. See the full table of the Quantified Greenhouse Gas Inventory attached to the report.



METHODOLOGIES FOR THE COLLECTION AND QUANTIFICATION OF DATA

The emissions summary reflects the consolidation of emissions data according to the Greenhouse Gas Protocol reporting standards. These being the Corporate Accounting and Reporting Standard (2004) and the Corporate Value Chain Accounting and Reporting Standard (2011).

The reported GHG are aggregated into the following category groups at the organisational level.

Scope 1 - Direct Emissions from operations.

Scope 2 - Indirect emissions from the use of purchased electricity, steam, heating, and cooling.

Scope 3 - Indirect emission in the value chain; further divided into upstream and downstream emissions.

**Carbon offsets are not reported in this report,
nor have they been subtracted from the total.**

REPORTED GHG AND GWP

The following greenhouse gases are included in the analysis: carbon dioxide (CO₂), methane (CH₄), nitrous oxide (N₂O), sulphur hexafluoride (SF₆), nitrogen trifluoride (NF₃), hydrofluorocarbons (HFCs) and perfluorocarbons (PFCs).

Emissions from these greenhouse gases are expressed in CO₂-equivalent (CO₂e) based on their global warming potential over a time horizon of 100 years (GWP100). The Global Warming Potential (GWP) values are based on the Intergovernmental Panel on Climate Change (IPCC) Fourth, Fifth or Sixth Assessment Report (AR4, AR5 or AR6), in accordance with the methodological choices of the emission factor publishers used in this report.

The split of the GHG emissions inventory into the individual contributions of each GHG (group) can be found in Appendix III. Activities for which a further split in greenhouse gasses is not known, are reported under the CO₂e*-column.

The emission factors for aviation were extended to include the additional effects of radiative forcing through the emission of gases and aerosols and changing cloud abundance. For this a central estimate for a multiplier to the GWP100 figure is used. This estimate tries to reflect the additional effect based on the best available scientific evidence, while being consistent with UNFCCC reporting convention. The total emissions in this report include electricity emissions using the market-based method. Travel emissions in this report include the effects of radiative forcing for aviation.



GREENHOUSE GAS PROTOCOL



APPROACH TO EMISSION FACTORS

For each activity the most relevant and localised emission factor possible has been selected, at the discretion of the reporter. Apart from locality and relevancy, other considerations were the availability of emission factors and consistency in the selection of emission factor publications throughout the document.



A full list of emission factor publications used in this report can be found in the table below:

Publisher	Publication Version	Publication Date	URL
Exiobase	3.8.2	21/10/2021	link
UK.gov	v2023 1.0	15/05/2023	link
Association of Issuing Bodies	2022 v1.0	26/05/2023	link

Each emission factor used in the calculation has an assigned validity period overlapping or partially overlapping with the application period of the reported activity. The validity period of emission factors is determined by its publication document^[1].

Approach to base year reporting:

The reporting period Y-2023 is the first GHG reporting period for ADAllen Pharma Ltd and counts as the base year for the current and future reporting cycles.

[1] In case the application period of the activity overlaps with the validity period of more than one emission factor, the median data of the activity period is used to determine which factor to use. (example if an activity stretches from August 2021 to July 2022, the median date is 29/01/2022)

UNCERTAINTY ASSESSMENT

For this report, a qualitative assessment of uncertainty has been applied. Seen that the effectiveness of a quantitative assessment would be limited due to a general lack of accurate uncertainty data. The applicability of these quantitative assessments will be reviewed in each subsequent reporting period.

The emissions inventory provided in the consolidated statement carries some degree of uncertainty, which can be attributed to the following causes:

- Uncertainty about the data collection methods of sources.
- Uncertainty about the input accuracy where large quantities of data are involved.
- Structural uncertainty in the methodology of emission factors.

ADAllen Pharma Ltd's commitment to transparency and accuracy in reporting its greenhouse gas (GHG) emissions is evident in the detailed uncertainty assessment provided.

This analysis is crucial for understanding the reliability of the reported data and highlights areas for continuous improvement. Below is a analysis of the uncertainty assessment for each activity group.

Activity Group	Emissions (tCO ₂ e)	Uncertainty	Share of total emissions
Electricity	2.69	-38% to +62%	5.3%
Goods & Services	19.56	-38% to +60%	38.6%
Energy Supply	1.2	-29% to +40%	2.4%
Transport Upstream	11.4	-40% to +67%	22.5%
Commuting	1.34	-28% to +40%	2.6%
Transport Downstream	14.44	-37% to +58%	28.6%
Total GHG emissions	50.65	-18% to +22%	100.0%

Uncertainty Range: -18% to +22%

UNCERTAINTY ASSESSMENT

The overall uncertainty range reflects a balanced approach to emissions reporting, emphasising accuracy and transparency.


Goods and services represent a significant portion of the total emissions. The wide range indicates the complexity of supply chain emissions and ADAllen Pharma Ltd's diligent efforts to account for these variables.

Continuing to refine data collection processes, collaborating closely with suppliers to obtain more precise data, and engaging in continuous improvement practices will reduce overall uncertainty and further minimise it.

ADAllen Pharma Ltd's detailed uncertainty assessment underscores the company's dedication to transparency and continuous improvement. By addressing the identified uncertainties through advanced data collection methods and supplier collaboration, the company aims to achieve more accurate emissions reporting.

Review, Internal Audit and Improvement

This emission inventory for reporting period has been compiled with highest attention for completeness and correctness.



CARBON FOOTPRINT ANALYSES:

The majority of ADAllen Pharma Ltd's carbon footprint lies within Scope 3 emissions, which total 54 tCO₂e. These emissions encompass various activities along the value chain:

Purchased Goods and Services:

The emissions from purchased goods and services for ADAllen Pharma Ltd are notably significant, totalling 20 tCO₂e. This underscores the substantial carbon impact associated with the materials and services the company procures.

Among these, IT stands out as the largest contributor, with a staggering 9871 KGCO₂e, far surpassing other categories. Following IT, insurance accounts for a considerable 2070 KGCO₂e. Other significant contributors include repairs and renewals, printing, post and stationery, accountancy, and legal fees, each adding to the overall emissions profile.

Upstream Transportation and Distribution:

Emissions from upstream transportation and distribution amount to 11.4 tCO₂e, indicating the carbon footprint associated with the movement of goods and materials to the company.

Downstream Transportation and Distribution:



Emissions from downstream transportation and distribution contribute 14.4 tCO₂e, highlighting the impact of distributing the company's products to end-users.

In summary, ADAllen Pharma Ltd's carbon footprint analysis reveals that the most substantial contributions to their greenhouse gas emissions come from activities within the value chain, particularly in purchased goods and services and upstream transportation.


To make significant progress in reducing their overall carbon footprint, the company should prioritise managing and mitigating Scope 3 emissions. Efforts to enhance supply chain efficiency, collaborate with suppliers, and adopt sustainable practices will be crucial steps in this direction.



- Mobile Combustion
- Electricity
- Goods & Services
- Energy Supply
- Transport Upstream
- Waste
- Commuting
- Transport Downstream



Emission Category	Scope	All GHG (tCO ₂ e)
Scope 1 - Direct Emissions from operations		0
Mobile Combustion	Scope 1	0
Scope 2 - Indirect Emissions from electricity consumption		5
Purchased electricity - market based	Scope 2	5
Purchased electricity - location based	Scope 2	3
Scope 3 - Indirect Emissions in the value chain - Upstream		35
Purchased goods and services	Scope 3	20
Fuel- and energy-related activities	Scope 3	2
Upstream transportation and distribution	Scope 3	11
Waste generated in operations	Scope 3	<1
Business travel	Scope 3	-
Employee commuting	Scope 3	1
Scope 3 - Indirect Emissions in the value chain - Downstream		14
Downstream transportation and distribution	Scope 3	14
		55



Goods & Services

Activity Category	sum(Emissions [KGCO ₂ e])		
Mobile Combustion	0		
Electricity	5389	5389	5389
Goods & Services	19564		49169
IT	9871		
Insurance	2070		
Repairs and renewals	1501		
Printing, post and stationery	1236		
Accountancy	943		
Legal fees	921		
Motor expenses	565		
Factoring charges	457		
Subscriptions	452		
Finance costs	411		
Other	1138		
Energy Supply	2396		
EV	240		
EL	2156		
Transport Upstream	11406		
Air Transport	853		
Outsourced Storage	6373		
Road Transport	4180		
Waste	23		
Commercial waste	13		
Water treatment	10		
Commuting	Commuting	1341	1341
Transport Downstream	Freight flights - international	5445	14438
	Chiltern Road	8993	
Total		54558	54558



ABOUT US

ADAllen Pharma Limited, a private company, was founded by our CEO, David Allen, in 2001 as a niche company specialising in sourcing licensed comparator drugs including Biosimilars for Clinical Trials. We have since expanded our operations to deliver all Clinical Trial product needs including ancillary supplies and now offer a range of services from expert project management to specialist Cold Chain storage. Our CEO has over 30 years' experience in the Pharmaceutical Industry starting out as a Qualified Pharmacist and later progressing to set up the Clinical Trial sourcing operations in the mid 90s.

CONTACT US

 +44 (0)1992 566 366

 info@adallenpharma.com

 www.adallenpharma.com

Prepared by :

